Since the majority of atrial fib patients are over 70 and therefore are at risk for renal dysfunction, Eliquis will have an advantage as it has lower renal excretion percentage than both Pradaxa and Xarelto.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.